key: cord-0772794-khn45tan
authors: Ren, Xianwen; Wen, Wen; Fan, Xiaoying; Hou, Wenhong; Su, Bin; Cai, Pengfei; Li, Jiesheng; Liu, Yang; Tang, Fei; Zhang, Fan; Yang, Yu; He, Jiangping; Ma, Wenji; He, Jingjing; Wang, Pingping; Cao, Qiqi; Chen, Fangjin; Chen, Yuqing; Cheng, Xuelian; Deng, Guohong; Deng, Xilong; Ding, Wenyu; Feng, Yingmei; Gan, Rui; Guo, Chuang; Guo, Weiqiang; He, Shuai; Jiang, Chen; Liang, Juanran; Li, Yi-min; Lin, Jun; Ling, Yun; Liu, Haofei; Liu, Jianwei; Liu, Nianping; Liu, Shu-Qiang; Luo, Meng; Ma, Qiang; Song, Qibing; Sun, Wujianan; Wang, GaoXiang; Wang, Feng; Wang, Ying; Wen, Xiaofeng; Wu, Qian; Xu, Gang; Xie, Xiaowei; Xiong, Xinxin; Xing, Xudong; Xu, Hao; Yin, Chonghai; Yu, Dongdong; Yu, Kezhuo; Yuan, Jin; Zhang, Biao; Zhang, Peipei; Zhang, Tong; Zhao, Jincun; Zhao, Peidong; Zhou, Jianfeng; Zhou, Wei; Zhong, Sujuan; Zhong, Xiaosong; Zhang, Shuye; Zhu, Lin; Zhu, Ping; Zou, Bin; Zou, Jiahua; Zuo, Zengtao; Bai, Fan; Huang, Xi; Zhou, Penghui; Jiang, Qinghua; Huang, Zhiwei; Bei, Jin-Xin; Wei, Lai; Bian, Xiu-Wu; Liu, Xindong; Cheng, Tao; Li, Xiangpan; Zhao, Pingsen; Wang, Fu-Sheng; Wang, Hongyang; Su, Bing; Zhang, Zheng; Qu, Kun; Wang, Xiaoqun; Chen, Jiekai; Jin, Ronghua; Zhang, Zemin
title: COVID-19 immune features revealed by a large-scale single cell transcriptome atlas
date: 2021-02-03
journal: Cell
DOI: 10.1016/j.cell.2021.01.053
sha: 87cadfbd116b8e8c7fb2d6751c8f659786282939
doc_id: 772794
cord_uid: khn45tan

Dysfunctional immune response in the COVID-19 patients is a recurrent theme impacting symptoms and mortality, yet the detailed understanding of pertinent immune cells is not complete. We applied single-cell RNA sequencing to 284 samples from 196 COVID-19 patients and controls and created a comprehensive immune landscape with 1.46 million cells. The large dataset enabled us to identify that different peripheral immune subtype changes were associated with distinct clinical features including age, sex, severity, and disease stages of COVID-19. SARS-CoV-2 RNAs were found in diverse epithelial and immune cell types, accompanied by dramatic transcriptomic changes within viral positive cells. Systemic up-regulation of S100A8/A9, mainly by megakaryocytes and monocytes in the peripheral blood, may contribute to the cytokine storms frequently observed in severe patients. Our data provide a rich resource for understanding the pathogenesis and developing effective therapeutic strategies for COVID-19.

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 94 coronavirus 2 (SARS-CoV-2) has caused >98 million infections and more than 2.1 million 95 deaths according to the statistics of World Health Organization until January 24, 2021. 96

Although many COVID-19 patients experience asymptomatic, mild or moderate symptoms, 97 some patients progress to severe conditions and even death. It is thus important to individuals, including hospitalized COVID-19 patients with moderate or severe disease, and 113 patients in the convalescent stage, as well as healthy controls. We reveal that SARS-CoV-2 114 RNA could be detected in a wide range of cell types, accompanied by distinct 115

transcriptomic changes between those SARS-CoV-2 RNA-positive and negative cells. We 116 also observed critical changes to COVID-19 clinical features. Further, our data provide a 117 resource to reveal the characteristics of cytokine storms in patients. Our data and findings 118 may have important implications to the understanding and controlling of COVID-19. 119

Integrated analysis of the COVID-19 scRNA-seq data 121 To characterize the immune properties of COVID-19, we formed a Single Cell Consortium 122

for COVID-19 in China (SC4), which consisted of researchers from 36 institutes or hospitals 123 from different regions of China. SC4 generated a scRNA-seq dataset for 171 COVID-19 124 patients including 22 with mild/moderate symptoms, 54 hospitalized patients with severe 125 symptoms, and 95 recovered convalescent persons (57 from mild/moderate and 38 from 126 severe symptoms), as well as 25 healthy controls according to the WHO classification 127

( Figure 1A and Table S1 ). 186/284 samples were unpublished. Patients with mild or 128 moderate symptoms were merged as one group but were further divided into progression 129 (moderate) or convalescence (moderate) based on the time of sample collection ( Figure 1A  130 and Table S1 ). Similarly, we merged patients with severe symptoms or in the critical stage 131 into one group ( Figure 1A and Table S1 ) and focused on analyzing the molecular and 132 cellular mechanisms underlying distinctions between mild/moderate and severe/critical 133 symptoms. This cohort covered an age range from 6 to 92 years old ( Figure S1A ), in which 134 aged patients were enriched in the severe groups, consistent with previous report (Huang 135 et al., 2020). Additionally, no significant difference was noted in the sex composition 136 between the moderate and severe groups ( Figure S1B ). 137

Among the 284 samples, 249 were from peripheral blood mononuclear cells (PBMCs)  138 with or without further sorting for B or T cells, and 35 were from the respiratory system, 139

including 12 bronchoalveolar lavage fluid (BALF) samples, 22 sputum samples, and 1 140 sample for pleural fluid mononuclear (PFMC) cells (Table S1 ). Seven patients had matching 141 BALF and PBMC samples collected. Most samples were subjected to scRNA-seq based on 142 the 10X Genomics 5' sequencing platform to generate both the gene expression and T cell 143 receptor (TCR) or B cell receptor (BCR) data (Table S1 ). Gene expression data were 144 obtained by the kallisto and bustools programs (Bray et al., 2016; Melsted et al., 2019) , and 145 TCR and BCR sequences were obtained by the CellRanger program. 146

We applied stringent quality control criteria to ensure that the selected data were from 147 single and live cells (Table S1 ). A total of 1,462,702 high-quality single cells were ultimately 148 obtained, with an average of 4,835 unique molecular identifiers (UMIs), representing 1,587 149 genes ( Figures S1C-E) . 64 cell clusters were derived, covering diverse cell types in the 150 respiratory system and peripheral blood ( Figure 1B ). Such an information-rich resource 151 (available at http://covid19.cancer-pku.cn/ for quick browsing) enabled accurate annotation 152

and analysis of these cell clusters at different resolutions (Figure S1F-J and Table S2 ). 153

Notable differences could be observed based on the t-distributed stochastic neighbor 154 embedding (t-SNE) projection ( Figure 1A ). The tissue preference of each cluster was 155 illustrated based on R O/E ( Figure 1C) , i.e., the ratio of observed to randomly expected cell 156 J o u r n a l P r e -p r o o f 4 numbers used for removing the technical variations on tissue preference estimation (Zhang 157 et al., 2018) . Notably, various clusters of proliferating CD8+ and CD4+ T, and plasma B 158 cells were more enriched in BALF than PBMCs ( Figure 1C) . Similarly, the preference of 159 each cluster in different patient groups was also illustrated ( Figure 1D ), with proliferative 160 and activated B and T cells and macrophages more enriched in severe COVID-19 patients 161 in the disease progression stage. 162

Association of patient age, sex, COVID-19 severity and stage with PBMC 163 compositions 164 We first analyzed the compositional changes of the broad categories of immune cells in 165 PBMC. Notably, the percentages of megakaryocytes and CD14+ monocytes in PBMCs 166

were elevated, particularly in severe COVID-19 patients during the disease progression 167 stage ( Figure S2A ). While NK cells did not show significant changes among the different 168 groups, B cells were significantly increased in severe COVID-19 patients but T cells and 169

DCs were decreased ( Figure S2A ), consistent with the lymphopenia phenomenon 170 previously reported (Chen and John Wherry, 2020). 171

The large cohort size enabled us to dissect the associations of age, sex, disease 172 severity and stage with the compositional changes of immune cells in PBMC. We applied 173 analysis of variance (ANOVA) to interrogate such associations based on 159 PBMC 174 samples each with >1000 single cells available. We also incorporated two technical factors 175 in the ANOVA model for controlling technical variations, i.e, sample type (fresh or frozen 176

PBMCs) and sample time (days after symptom onset). After multiple testing correction, 177 significant associations were found ( Figure 2A) . Notably, while most B cell clusters were 178 associated with the disease recovery status, XBP1+ plasma cells (B_c05-MZB1-XBP1) 179 showed association with COVID-19 severity ( Figure 2A) . XBP1, POU2AF1, PRDM1 and 180

IRF4 were highly expressed in B_c05-MZB1-XBP1 (Table S2) , confirming this cluster as 181 plasma cells (Todd et al., 2009 ). Percentage of plasma cells could reach 15% in severe 182 COVID-19 patients, but none of other individuals could reach 3% ( Figure 2B ). Such 183 increase was observed irrespective to the sample types (fresh or frozen, Figure 2B ), 184

indicating the robustness of this observation. Similarly, such increase was also irrespective 185 of sampling time (Figure 2A and S3A). These plasma B cells in PBMCs highly expressed 186 the genes encoding the constant regions of IgA1, IgA2, IgG1 or IgG2 ( Figure 2C ), implying 187 their functions to secrete antigen-specific antibodies. This observation is consistent with the 188 previous finding that serum of severe COVID-19 patients had high titers of SARS-CoV-2-189 specific antibodies (Ni et al., 2020) . 190

The increase of plasma B cells in PBMC appeared to be derived from active 191 proliferation and transitions from memory B cells based on the BCR analysis ( Figure S2B ). 192

Plasmablast cells (B_c06_MKI67), characterized by high expression of MKI67 and thus 193 indicating a proliferative state, were elevated in the peripheral blood of severe patients and shared the most clonotypes with plasma cells ( Figure S2B and S2C). The 195 memory B cell cluster (B_c03-CD27-AIM2), expressing relatively high levels of CD27, 196 CD80, AIM2, GRIP2, and COCH, was the second major source of plasma B cells and 197

shared a large proportion of clonotypes with plasma cells and plasmablasts ( Figure S2B ). 198

Transition from B_c03-CD27-AIM2 to B_c05-MZB1-XBP1 was supported by BCRs ( Figure  199 S2B) and RNA velocity analysis ( Figure S2D ). Similarly, the plasmacytoid dendritic cell 200 cluster DC_c4−LILRA4 was decreased in severe COVID-19 patients in both the 201 progression and convalescence stages, irrespective to sample processing methods or 202 sampling time ( , was associated with patient age, COVID-19 severity and stage after correcting  204  technical covariates (Figure 2A, 2E, and S3C).  205   For T cells, diverse proliferative T cell subsets, marked by high levels of MKI67,  206 exhibited distinct associations with COVID-19 severity and stage ( Figure 2A ). Two 207 proliferative CD4+ T cell clusters were identified, with T_CD4_c13-MKI67-CCL5 low 208 characterized by high SELL and low CCL5 and T_CD4_c14-MKI67-CCL5 high characterized 209 by low SELL and high CCL5, among others (Table S2) . T_CD4_c13-MKI67-CCL5 low cells 210

were elevated in COVID-19 patients, particularly in severe patients during the disease 211 progression stage ( Figure 2F ). Three proliferative CD8+ T cell clusters were identified, 212

including T_CD8_c10-MKI67-GZMK, T_CD8_c11-MKI67-FOS, and T_CD8_c12-MKI67-213 TYROBP. They were increased in COVID-19 patients but with different associations with 214 COVID-19 severity ( Figure 2A ). T_CD8_c10-MKI67-GZMK, a proliferative effector memory 215 CD8+ T cell group characterized by high STMN1, HMGB2, MKI67, and GZMK, was 216 increased in severe COVID-19 patients particularly in the convalescence stage ( Figure 2G ). 217

The variations of proliferative CD8+ T cell clusters in different severity and stages may 218

indicate the complexity of T cell responses induced by SARS-CoV-2 infection. 219

Unlike the B cell cluster B_c03-CD27-AIM2, which increased in peripheral blood 220 ( Figure S2E ), T_CD4_c04−ANXA2, a major source of proliferative CD4+ T cells, was 221 decreased in COVID-19 patients, particularly in severe patients during the disease 222 progression stage ( Figure S2F and S2G). Such increase of proliferative CD4 T cells and 223 decrease of their precursor cells in severe COVID-19 patients may partially explain the 224 dichotomous and incomplete adaptive immunity previously observed (Gao et al., 2020) . 225

Interestingly, naïve CD8+ T cells (T_CD8_c01−LEF1) exhibited the most significant 226 association with patient age among T cells (Figure 2A and Figure 3A and Table S3 ). A diverse set of B 244

and T cell subsets showed associations with COVID-19 severity ( Figure 3A ). As exemplified 245 by T_CD4_c02−AQP3 ( Figure 3B ), T_CD4_c08−GZMK−FOS high ( Figure 3C ), 246

T_CD8_c01−LEF1 ( Figure 3D ), and T_CD8_c02−GPR183 ( Figure 3E ), the TCR diversity of 247 these T cell subsets tended to be smaller in severe COVID-19 patients than those 248 moderate ones particularly in the disease progression stage. Among these clusters, certain 249 J o u r n a l P r e -p r o o f 6 T cell subsets also showed sex-and age-associated variations ( Figure 3A ), as exemplified 250 by T_CD4_c08−GZMK−FOS high ( Figure 3F ), T_CD8_c01−LEF1 ( Figure 3G ), 251

T_CD8_c05−ZNF683 ( Figure 3H ), and T_CD8_c09−SLC4A10 ( Figure 3I ). In general, the 252 diversity of these T cell subsets was higher in females than males, and in the youths than 253 older individuals . While the diversity of certain B and T cell subsets was affected by the  254  technical variations including sample processing methods and sampling time, ANOVA  255  dissected the effects of clinical features from such technical considerations and identified  256 associations robust to the technical interference ( Figure 3A and S3D-S3K). 257

We further examined whether identical TCRs or BCRs could be identified across 258 COVID-19 patients, but found very limited sharing (4 BCR clonotypes in 2 patients experimentally verified neutralizing antibodies ( Figure 3J ). Of note, the VDJ usage of the 273 currently known SARS-CoV-2-neutralizing antibodies was biased towards IGHV3 and 274 IGHV1 ( Figure 3J ). In particular, more than 40 neutralizing antibodies used IGHV3−53. 275

Such observations and the data may be important for identifying new neutralizing 276

antibodies. 277 SARS-CoV-2 RNAs detected in multiple epithelial and immune cell types 278 From the six BALF and two sputum samples of severe COVID-19 patients in the disease 279 progression stage, we detected viral RNAs of SARS-CoV-2 in 3085 cells from ciliated, 280 secretory, and squamous epithelial cells and a diverse set of immune cells including 281 neutrophils, macrophages, plasma B cells, T cells, and NK cells ( Figure 4A , Table S4 ). 282

Fewer cells were obtained in BALF from moderate COVID-19 patients and no SARS-CoV-2 283

RNAs were detected. The identity of these SARS-CoV-2 RNA-positive cells was confirmed 284

by the corresponding marker genes ( Figure 4B ). Interestingly, the immune cells harbored 285 even more viral RNA sequences than the epithelial cells ( Figure 4C ). Because ACE2 and 286 TMPRSS2 play critical roles in mediating SARS-CoV-2 entry (Hoffmann et al., 2020; Zhou 287 et al., 2020), we examined their expression levels in these cells ( Figure 4D ). We found that 288

ACE2 and TMPRSS2 were expressed in a subset of those epithelial cells. However, those 289 immune cells did not express ACE2 or TMPRSS2. , S4B and Table S4 ). Compared with matched cell types in PBMC which 300

were negative for SARS-CoV-2 RNAs, ISG genes exhibited elevated expression in these 301 viral RNA-positive immune cells ( Figure S4B , and Table S5 ). Compared with viral RNA-302 negative immune cells of the same types in the BALF, SARS-CoV-2 RNA-positive epithelial 303 cells, including ciliated, secretory, and squamous cells, as well as those virus RNA-positive 304 neutrophils, exhibited higher levels of ISG expression (Table S5 ). Positive correlations 305 between the abundance of viral RNAs and ISG expression levels were observed for most 306 cell types after removing potential dropouts in scRNA-seq ( Figure S4C ). 307

We then examined the detection rates of different SARS-CoV-2 genes in these cells 308

( Figure 4G ). In our cohort, SARS-CoV-2 RNA-positive immune cells were detected in 309 different research centers based on either 10x Genomics 5' or 3' sequencing platforms. 310

Since coronaviruses are characterized by subgenomic transcription and the genome of 311 SARS-CoV-2 is a single and positive RNA strand, genes close to the 3' end of the genome 312 were expected to have higher detection rates than those close to the 5' end if subgenomic 313 transcription occurred. In fact, both 10x 5' and 3' sequencing data demonstrated a 3'-314 enriched detection pattern along the SARS-CoV-2 genome in the viral RNA-positive cells, 315 reminiscent of the subgenomic transcription, in contrast to those cells without detectable 316 SARS-CoV-2 RNA ( Figure 4G and S4D). Since both 5' and 3' sequencing platforms 317 detected consistent patterns along the genome, the positive and negative strands of the 318 SARS-CoV-2 genome (at least sub-genomes) likely both existed in these cell types, 319

implicating active viral replication and transcription. We further validated the presence of 320 viral signal in lymphocytes with IHC staining of the viral spike protein in the lung tissue from 321 a severe COVID-19 patient ( Figure 4H and S4E). The presence of SARS-CoV-2 RNAs in different epithelial cells seemed to be associated 333 with additional transcriptomic changes. For squamous epithelial cells, SARS-COV-2 RNA-334 positive cells exhibited elevated expression of a diverse set of genes such as NT5E, 335

CLCA4, and SULT2B1 ( Figure 5A ). These genes were enriched in pathways such as 336 "response to virus", "response to type I interferon" and "response to hypoxia" ( Figure 5B ). 337

By contrast, the numbers of differential genes between SARS-CoV-2 RNA-positive and 338 negative ciliated epithelial cells were much smaller, and few genes showed consistent 339 changes in all the three epithelial cell types ( Figure 5C ). 340 J o u r n a l P r e -p r o o f 8 We next explored the potential impact of the above transcriptomic changes. Annexin 341 A1 (ANXA1), up-regulated in SARS-CoV-2 RNA-positive squamous epithelial cells ( Figure  342 S5A), is known to regulate the functions of neutrophils in inflammation via its interactions 343 with formyl peptide receptors (Sugimoto et al., 2016) . This prompted us to investigate the 344 potential cellular interaction differences between SARS-CoV-2 RNA-positive and negative 345 cells. Based on CSOmap, a bioinformatics tool to estimate cell-cell interactions in three-346 dimensional space via ligand-receptor mediated cell self-organization and competition (Ren 347 et al., 2020), we estimated the cellular interaction potentials in a computationally 348 constructed pseudo-space. We found that SARS-CoV-2 RNA-positive ciliated, secretory, 349

and squamous epithelial cells exhibited distinct interaction potentials between the severe 350 and moderate groups ( Figure 5D ). we hypothesize that they might also play important roles in the pathogenesis of COVID-19. 376 ANXA1, FPR1, S100A9, S100A8, and TLR4 also exhibited systemic changes in a wide 377 range of immune cells between moderate and severe COVID-19 patients ( Figure S6A and 378 S6B). Interestingly, for most immune cell clusters in BALF, the expression levels of ANXA1 379

and FPR1 were down-regulated in severe COVID-19 patients compared with those of 380 moderate COVID-19 patients ( Figure S6B ). But in PBMCs, except for MAIT cells 381

(T_CD8_c09-SLC4A10) and γδT cells (T_gdT_c14-TRDV2), ANXA1 and FPR1 were 382 significantly up-regulated in multiple cell types in severe COVID-19 patients ( Figure S6A ). 383

For severe COVID-19 patients in the disease progression stage, S100A9 and S100A8 were 384 significantly up-regulated in almost all cell clusters for both BALF and PBMCs ( Figure S6A  385 and S6B). In particular, the levels of S100A9 and S100A8 were even significantly up-386 regulated in T, B, NK, and dendritic cells compared to moderate patients ( Figure S6A and 387 9 S6B), indicating a systemic inflammatory response. TLR4 did not exhibit notable differences 388

in PBMCs between severe and moderate COVID-19 patients ( Figure S6A ) but was 389 significantly down-regulated in certain BALF monocyte and macrophage subsets ( Figure  390 S6B). 391

Megakaryocytes and monocyte subsets as critical peripheral sources of 392 cytokine storms 393 We next sought to investigate the potential sources of cytokine production. We first defined 394 a cytokine score and inflammatory score for each cell based on the expressions of the 395 collected cytokine genes and reported inflammatory response genes (Liberzon et al., 2015) 396 (Table S6) , respectively, and used these two inter-related scores as indicators to evaluate 397 the potential contribution to inflammatory cytokine storm for each cell. We found apparent 398 elevated expression of cytokine and inflammatory genes in patients, especially at the 399 severe progression stage ( Figure 6A and S7A), indicating the existence of inflammatory 400 cytokine storm. Seven cell subtypes, including three subtypes of monocytes (Mono_c1-401 CD14-CCL3, Mono_c2-CD14-HLA-DPB1 and Mono_c3-CD14-VCAN), three subtypes of T 402 cells (T_CD4_c08-GZMK-FOS high , T_CD8_c06-TNF and T_CD8_c09-SLC4A10) and one 403 subtype of megakaryocytes were detected with significantly higher cytokine and 404

inflammatory scores based on our scRNA-seq data for PBMC samples ( Figure S7B , Table  405 S7, P < 0.0001), indicating that these cells might be major sources of inflammatory storm. 406

Interestingly, megakaryocytes, which have been connected to the inflammatory response in 407 COVID-19 patients (Manne et al., 2020; Thachil and Lisman, 2020), may affect the 408 functions of platelets at the disease stage, consistent to a previous study (Manne et al., 409 2020). By contrast, eight cell subtypes exhibited higher cytokine scores even though their 410 inflammatory scores showed no difference to other cell clusters ( Figure S7B , Table S7 , p < 411 0.0001). 412

We then investigated the proportion of each of the 7 cell subtypes in patients and found 413 that these hyper-inflammatory cell subtypes were enriched in severe patients ( Figure S7C ). 414

The proportion of these hyper-inflammatory cell subtypes in PBMC showed different 415 enrichment patterns in patient groups ( Figure 6B ). Mono_c1-CD14-CCL3 was highly 416 enriched in a subpopulation of severe patients likely to be accompanied by inflammatory 417 storm ( Figure 6C ), and the proportion of these cells was also correlated with the age of the 418 corresponding patients ( Figure 6D ). The hyper-inflammatory megakaryocytes were 419 enriched in another batch of severe patients, who could also be under excessive 420 inflammatory response ( Figure 6B and 6C). To determine whether the two cell types 421

influence the immune state of severe patients, we further compared the inflammatory 422 scores of severe patients according to whether they were enriched with the two type of cells 423

( Figure S7D ). Patients with one of both cell types showed higher scores than those with 424 neither ( Figure S7E ). 425

By contrast, Mono_c2-CD14-HLA-DPB1 and Mono_c3-CD14-VCAN subtypes were 426 widely distributed in every disease stage, and the hyper-inflammatory T cells showed 427 decreased proportions in severe patients at the progression stage such as T_CD4_c08-428 GZMK-FOS high subtype ( Figure 6B , 6C and S7B), although both of these two monocyte 429

subtypes exhibited increased proportions in elder convalescent patients ( Figure 6D ). Taken  430 together, Mono_c1-CD14-CCL3 and megakaryocytes might be the major sources in 431

PBMCs triggering cytokine inflammatory storm, with cell ratios, inflammatory expression, or 432 both elevated in the severe COVID-19 patients. Certain T cell subtypes might also 433 contribute to the inflammatory storm by enhanced expression of pro-inflammatory cytokines. 434

Next, we investigated the inflammatory signatures for each hyper-inflammatory cell 435 subtype and found unique pro-inflammatory cytokine gene expressions in each cell subtype 436 (Figure 6E), such as TNF, CCL3, IL1B, CXCL8, IL6, TGFB1, LTB and IFNG, suggesting  437 diverse mechanisms potentially resulting in cytokine storms. The hyper-inflammatory 438

Mono_c1-CD14-CCL3 largely expressed more cell-type specific cytokines, suggesting 439 central roles of the two cell types in driving the inflammatory storm. In particular, Mono_c1-440 CD14-CCL3 highly expressed CCL3, IL1RN, and TNF, which were detected at much higher 441 levels in plasma from another cohort of patients at the severe stage, especially those 442 critically ill patients ( Figure 6E and S7F). For 19 patients, we collected both the scRNA-seq 443 data and the cytokine detection results using the plasma (Table S7) . Both data supported 444 that the severe patients contained higher level of multiple pro-inflammatory cytokines, such 445 as IL1B, TNF, IL-6 and CCL3 ( Figure 6F ). This further confirmed the accuracy of our 446

scRNA-seq analysis. Although the inflammatory megakaryocytes highly expressed cell type 447

identity marker genes such as PPBP (Zhang et al., 1997) , the expression level of these 448 genes was decreased in patients compared to healthy controls, indicating a loss of function 449 of these cells after inflammatory activation ( Figure 6E and 6G). Notably, the T_CD8_c06-450

TNF subtype specifically and highly expressed IFNG, a pro-inflammatory cytokine highly 451 enriched in patients at the progression (severe) stage, was also confirmed by plasma 452 cytokine detection ( Figure 6E , G and S7F). Moreover, pro-inflammatory cytokines CXCL8 453

and IFNG showed age-dependent expressions in patients with disease progression, while 454 no significance was observed in healthy controls ( Figure 6H ). These age-dependent 455 expressions of pro-inflammatory cytokines in COVID-19 patients could not be observed in 456 influenza patients ( Figure S7G and S7H), consistent with a recent study that reported 457 similar patterns of immune cells between aging and COVID-19 patients . 458

PPBP showed no correlation with the age in either patients or healthy controls, suggesting 459 that the potential loss of function of megakaryocytes might not be age-dependent ( Figure  460 6H). 461

462 blood 463 Cytokine storm may cause immunopathological injury to the lung, and large amount of 464 infiltrating inflammatory immune cells have been demonstrated in the pulmonary tissue of 465 COVID-19 patient (Cao, 2020) . We compared the inflammatory and cytokine scores among 466 all the cell subtypes captured in BALF. No enrichment of cytokine genes was observed from 467 the epithelial cells, while subtypes of macrophages and monocytes had the highest cytokine 468 and inflammatory scores in the progression (severe) samples ( Figure 7A ). Similar to our 469 analysis on PBMCs, we identified five hyper-inflammatory cell subtypes, including 470

Macro_c2-CCL3L1, the three subtypes of monocytes and the neutrophils ( Figure 7B ), 471

suggesting that these cell subtypes might be the major sources driving inflammatory storm 472 in the lung tissue. Neither CD4+ nor CD8+ T cells were detected with an elevated 473 inflammatory score or the cytokine score in BALF samples, which was different from those 474 in PBMCs. Each hyper-inflammatory subtype highly expressed specific cytokines; for 475 example, Macro_c2-CCL3L1 specifically expressed CCL8, CXCL10/11, and IL6. Mono_c1-476 CD14-CCL3, as one of the most notable proinflammatory cell types in both peripheral blood 477 and BALF, uniquely expressed high levels of IL1B, CCL20, CXCL2, CXCL3, CCL3, CCL4, 478

HBEGF and TNF. The neutrophils also showed multiple uniquely expressed cytokines 479

including TNFSF13B, CXCL8, FTH1, CXCL16 ( Figure 7C ). 480

We reasoned that the systematic inflammatory storm might also associate with cellular 481 cross-talks between lung and peripheral blood via secreting diverse cytokines. To examine 482 J o u r n a l P r e -p r o o f 11 this, we analyzed the ligand-receptor pairing patterns among hyper-inflammatory cell 483 subtypes in severe and moderate samples within PBMC and BALF respectively ( Figure S8 ). 484

The interactions between PBMCs and BALF cells appeared to show significant alterations 485 ( Figure 7D ). Our data revealed elevated ligand-receptor interactions of hyper-inflammatory 486 cells in patients at severe compared to moderate stage. Interestingly, cells in the peripheral 487 blood of severe patients showed much lower interactions with each other compared to 488 those in BALF ( Figure S8A ), except for the megakaryocytes, which expressed IL1B and 489 could potentially stimulate Mono_c1-CD14-CCL3 cells. Mono_c1-CD14-CCL3 cells in BALF 490 expressed CCR5, which could receive multiple cytokine stimuli secreted by other cell types 491

in both the lung tissue and the peripheral blood. By contrast, the interactions of Macro_c2-492 CCL3L1 cells mainly relied on CCR2 and IL1R2. Collectively, these findings illustrated the 493 molecular basis for the potential cell-cell interactions at the pulmonary interface in an 494

inflamed state in the COVID-19 patients. 495

Our SC4 alliance members generated scRNA-seq data for 284 clinical samples from 196 497 COVID-19 patients and healthy controls in China, and constructed an information-rich data 498

resource for dissecting the immune responses of COVID-19 patients at the single-cell 499

resolution. This dataset covered both lung and blood samples of COVID-19 patients with a 500 wide age range, balanced sex ratio, moderate and severe symptoms, and both progression 501 and convalescence stages. Sixty-four well-annotated cell subsets were clustered, providing 502 fine details of the cellular and molecular responses to SARS-CoV-2 infection. 503

The comprehensive nature of our dataset proved to be powerful at dissecting the 504 associations of age, sex, disease severity and stage with the diverse immune subsets in 505 SARS-CoV-2 infection. In general, plasma B and proliferative T cells were associated with 506 disease severity, while compositional differences of the precursor cells of these adaptive 507

immune cell types were more prone to be influenced by sex and age. Of note, age and sex 508 also seemed to impact the diversity of TCR/BCR repertoires for a wide range of T and B 509 cells, which may have clinical implications. 510

We also demonstrated the presence of SARS-CoV-2 sequences in both epithelial and 511

immune cells, along with any altered transcriptomic properties. The presence of viral 512 sequences in multiple epithelial cell types in the human respiratory tract, including ciliated, 513 secretory, and squamous cells, is likely explained by viral infection, although the 514 consequences of viral presence appear to be distinct. The presence of SARS-CoV-2 RNAs 515 in various immune cell types, including neutrophils, macrophages, plasma B cells, T and 516 NK cells, was surprising to us initially, but such phenomenon is starting to be appreciated 517 by the research community. While it is still not clear how such immune cells would acquire 518 viral sequences, our findings provide tractable angles to further explore these important 519

questions. It appears to us that such viral presence in immune cells, through infection or 520 otherwise, is not without functional consequences. 521

In our attempt to dissect the cellular origins of potential cytokine storms, we found that 522 megakaryocytes and a few monocyte subsets might be key sources of a diverse set of 523 cytokines highly elevated in COVID-19 patients with severe disease progression. Potential 524 cross-talks between lung and peripheral blood could be abstracted from our dataset as 525 exemplified in Figure S8B , facilitating future studies. 526 12 In summary, the large scRNA-seq dataset covering diverse disease severity and 527 stages has revealed multiple immune characteristics of S COVID-19 that were not 528 adequately appreciated previously. Such data provide a critical resource and important 529 insights in dissecting the pathogenesis of COVID-19, and potentially help the development 530 of effective therapeutics and vaccines against SARS-CoV-2. 531 19 patients and healthy controls. Clusters were named based on the specific gene 580 expression patterns, in which we used high" or "low" to indicate the relative expression 581 levels in the corresponding clusters. Genes without "high" or "low" labels were specifically 582 expressed in the corresponding clusters. See also Figure S1 , Tables S1 and S2. 586 See also Figure S2 and Table S3 . 597 See also Figure S3 and Table S3 . 613 See also Figure S4 and Tables S4 and S5 . 628 See also Figure S5 and S6. 652 profiling for healthy controls (n=20 for scRNA-seq, and n=5 for plasma), convalescence 668 (severe, n=5, for both scRNA-seq and plasma) and progression (severe, n=14, for both 669 scRNA-seq and plasma). See also Figure S7 , Table S6 and S7. 687 See also Figure S8 and Table S6 . rate was set to be 0.08, and cells predicted to be doublets or with doubletScore larger than 944 0.25 were filtered. After quality control, a total of 1,598,708 cells were remained. The 945 stepwise quality control metrics used for individual samples were listed in Table S1 . The 946

resulting distribution of UMI counts, gene counts as well as mitochondrial gene percentage 947

were shown in Figure S1C -E. We normalized the UMI counts with the deconvolution 948 strategy implemented in the R package scran. Specifically, cell-specific size factors were 949 computed by computeSumFactors function and further used to scale the counts for each 950 cell. Then the logarithmic normalized counts were used for the downstream analysis. 951 952 To covariates for correction with theta set as 2.5 and 1.5, respectively. The resulting batch-962 corrected matrix was used to build nearest neighbor graph using Scanpy (Wolf et al., 2018) . 963

Such nearest neighbor graph was then used to find clusters by Louvain algorithm (Traag et  964 al., 2019). The cluster-specific marker genes were identified using the rank_genes_groups 965 function. 966

The first round of clustering (resolution = 0.3) identified six major cell types including T cells,

within each major cell type, we performed a second round of clustering on T/NK, B/plasma 969 B, myeloid and epithelial cells separately. The procedure of the second round of clustering 970 is the same as first round, starting from low-rank harmony output (30 components) on the 971 highly variable genes chosen as described above, with resolution ranging from 0.3 to 1.5. 972

Each sub cluster was restrained to have at least 30 significantly highly expressed genes 973 (FDR < 0.01, logFC > 0.25, t test) compared with other cells. Annotation of the resulting 974 clusters to cell types was based on the known markers. Meanwhile, single cells expressing 975 two sets of well-studied canonical markers of major cell types were labeled as doublets and 976 excluded from the following analysis. Also, cells highly expressed HBA, HBB and HBD, 977

which are the markers for erythrocytes, were also excluded. 136,006 cells were removed 978 and a total of 1,462,702 cells were retained for downstream analysis. In total, we identified Figures 1B, S1F-J) . A full list of canonical and signature marker genes for each cluster was 984 deposited in Table S2 . 985

Detection and processing scRNA-seq data with viral RNA 986 To identify single cells with viral RNA, we aligned raw scRNA-seq reads using 987 kallisto/bustools (KB) against a customized reference genome, in which the SARS-CoV-2 988 genome (NC_045512, NCBI Refseq) was added as an additional chromosome to the 989 human reference genome. Single cells with viral reads (UMI > 0) were retained. Cells with 990 less than 200 genes expressed or more than 20% mitochondrial counts were excluded, as 991 well as those labeled as doublet following aforementioned protocol ( Figure 4A ). 992

The remaining cells were then used for dimension reduction and unsupervised clustering 993

using Python package Scanpy. In brief, the top 500 genes with the highest variance were 994 selected and the dimensionality of the data was reduced by principal component analysis 995

(PCA) (30 components) first and then with t-SNE, followed by Louvain clustering performed 996 on the 30 principal components (resolution = 1). For t-SNE visualization, we directly fit the 997 PCA matrix into the scanpy.api.tl.tsne function with perplexity of 30. To identify cell-type-998 specific gene markers, we selected genes that were differentially expressed across different 999 cell types (FDR < 0.01, log fold change > 0.5) using the rank_genes_groups function. 1000

Clusters were annotated based on the expression of known marker genes ( Figure 4B ). 1001

To confirm whether the virus detection rate is related to library preparation methods, we 1002 further aligned raw scRNA-seq reads against the same reference genome with additional 1003 annotation information of the 11 SARS-CoV-2 genes. We then calculated detection rates in 1004

10x 3-prime and 10X 5-prime sequencing samples respectively ( Figure 4F and Figure S4G ). 1005 We could directly calculate the detection rate ( ) of each gene by the equation: 1006 = × 1007 denotes the number of cells within cell type while denotes the number of cells with 1008 gene detected within . is the length of gene . 1009 1010 TCR/BCR sequences were assembled and quantified following Cell Ranger (v.3.0.2) vdj 1011 protocol against GRCh38 reference genome. Assembled contigs labeled as low-confidence, 1012

non-productive or with UMIs < 2 were discarded. To identify TCR clonotype for each T cell, 1013

only cells with at least one TCR α-chain (TRA) and one TCR β-chain (TRB) were remained. 1014

For a given T cell, if there are two or more α or β chains assembled, the highest expression 1015 level (UMI or reads) α or β chains was regarded as the dominated α or β chain in the cell. 1016

Each unique dominated α-β pair (CDR3 nucleotide sequences and rearranged VDJ genes 1017 included) was defined as a clonotype. T cells with exactly the same clonotype constituted a 1018 T cell clone. 2B-G, 2I, and 3B-F). We performed correlation analysis to assess the association between 1048 cell type proportion and patient age ( Figures 2H and 3G-I) . Only those cell types with 1049 statistically significant differences (FDR < 0.05) in proportions were shown. 1050 ANOVA analysis 1051 To further assess how different patients' phenotypes and their potential interactions 1052 influence cell type proportions, we performed multivariate ANOVA on cell type proportions 1053 and on diversity of BCR/TCR based on different patient phenotypes (Figures 2A and 3A) , 1054

including disease severity, disease progression stage, sex and age together with technical 1055 factors including sample type (fresh or frozen) and sampling time (days after symptom 1056 onset). Interactions between these variables were excluded. To convert age into a 1057 categorical variable, we binned patient age into four groups: young (<18 years old), middle-1058 age (18-50 years old), old-age (50-70 years old) and the elderly (70+ years old). 1059

Interactions between variables were regarded as significantly associated with cell type 1060

proportions when FDR < 0.05. Sampling time was binned into five groups: controls; <10 1061 days; 10-30 days; 30-60 days; >60 days. 1062 1063 To investigate the impact of the presence of the viral RNA on epithelial cells, we identify 1064 differential expressed genes by performing two-sided unpaired Wilcoxon tests on all the 1065 expressed genes (expressed in at least 10% cells in either group of cells). P values were 1066 adjusted following Benjamini & Hochberg protocol. Top 100 highly expressed genes of each 1067 group were shown in the volcano plots ( Figure 5A ). Based on these genes, enriched GO 1068 J o u r n a l P r e -p r o o f 26 terms were then acquired for each group of cells using R package clusterProfiler (Yu et al., 1069 2012) following the default parameters. Annotation Dbi R package "org.Hs.eg.db" was used 1070

to map gene identifiers. The results were visualized as bar plots ( Figure 5B) . 1071 1072 To illustrate the cell-cell interaction potential of cells with viral detection, we first created a 1073 set of datasets by joining 7 BALF samples with the virus+ dataset separately. Then, we 1074

used CSOmap to construct a 3D pseudo space and calculate the 1075 significant interaction for each dataset. To investigate the interaction potentials of the cell 1076 types, we used two indexes, distances within cell type and normalized connection. Distance 1077 within each cell type is calculated based on the aforementioned 3D coordinates (Figures 5E,  1078 F and G). The shorter the distance, the closer the cells are located in the 3D space, which 1079

indicates that they are more likely to interact with each other. To further investigate the 1080 interaction between different cell types, we made use of the CSOmap output connection 1081 matrix ( Figure 5I ). For a cluster pair, normalized connection was calculated by dividing its 1082 corresponding connection value by the product of their respective cell numbers. Normalized 1083 connections were then multiplied by 10,000. Meanwhile, to highlight the key ligand-receptor 1084 pairs function in the interaction, we also examine the contribution output by CSOmap 1085

( Figure 5H ). 1086

Inflammatory and cytokine score related subtypes analysis. 1087 Briefly, we firstly filtered out samples with fewer than 1000 cells available. For PBMC, only 1088 subtypes with more than 1000 cells were included in the subsequent analysis. For BALF 1089 data analysis, we removed major cell types with fewer than 500 cells. To define 1090 inflammatory and cytokine score, we downloaded a gene set termed 1091 'HALLMARK_INFLAMMATORY_RESPONSE' from MSigDB (Liberzon et al., 2015) and 1092

collected cytokine genes based on these references (see Table S1 ). Cytokine and 1093

inflammatory score were evaluated with the AddModuleScore function built in the Seurat 1094 (Stuart et al., 2019) . To select the most promising hyper-inflammatory cell types, we 1095

performed Mann-Whitney rank test (single-tail) for each subtype's score versus all the other 1096 subtypes' score. Seven subtypes (Mono_c1-CD14-CCL3, Mono_c2-CD14-HLA-DPB1, 1097

Mono_c3-CD14-VCAN, T_CD4_c08-GZMK-FOS high , T_CD8_c06-TNF, T_CD8_c09-1098 SLC4A10 and Mega) in PBMC were defined as hyper-inflammatory cell types with 1099 significantly statistical parameters (P < 0.0001) in both cytokine and inflammatory score. In 1100 addition, we defined 8 subtypes (T_CD8_c08-IL2RB, T_CD4_c11-GNLY, NK_c01-FCGR3A,  1101 T_CD8_c05-ZNF683, T_CD8_c04-COTL1, T_CD8_c07-TYROBP, T_CD8_c03-GZMK and 1102

T_gdT_c14-TRDV2) with significantly statistical parameters (P < 0.0001) only in cytokine 1103 score. For subtypes in BALF, we defined 5 subtypes (Macro_c2-CCL3L1, Mono_c1-CD14-1104 CCL3, Mono_c2-CD14-HLA-DPB1, Mono_c3-CD14-VCAN, Neu) as hyper-inflammatory 1105 types with the same standard threshold as PBMC (P < 0.0001). 1106 1107 To explore whether there are state-specific of COVID-19 patients enriched subtypes, we 1108 performed hierarchical clustering with setting standard scale (0-1) for 7 hyper-inflammatory 1109 subtypes ( Figure 6B ). Then, we used the Wilcoxon rank-sum test to calculate the 1110 significance of cell proportion of each subtype in states (moderate convalescent, moderate 1111 progression, severe convalescent, severe progression) compared with healthy control 1112

( Figures 6C and G) . We also applied the ordinary least square method to calculate the 1113 correlation between age and cell proportion in different states of COVID-19 patients 1114 J o u r n a l P r e -p r o o f 27 ( Figures 6D and H) 1132 To identify and visualize the possible cell-cell interactions in terms of cytokine storm 1133 between the highly inflammation-correlated cell types evaluated by the inflammation score 1134

within each tissue and the crosstalk between lung and circulating blood, we employed an R 1135 package iTALK introduced by Wang et al. (Wang et al., 2019 , bioRxiv, 1136 https://www.biorxiv.org/content/10.1101/507871v1). Cytokine/chemokine category (n = 320) 1137

in the ligand-receptor database was selectively used for our purpose. Wilcoxon rank sum 1138 test was used to identify the differentially expressed genes (DEGs) between the 1139 progression (severe) and progression (moderate) patient groups for each cell type. DEGs 1140

were then matched and paired against the ligand-receptor database to construct a putative 1141 cell-cell communication network. An interaction score defined as the product of the log fold 1142 change of ligand and receptor was used to rank these interactions ( Figure 7D ). In addition, 1143 the expression level of both ligand and receptor were also considered. We defined severe 1144 gained interaction if a ligand gene was upregulated in the progression (severe) group and 1145 its paired gene upregulated or remains no change. We defined severe lost interaction if a 1146 ligand (receptor) gene was downregulated in the progression (severe) group regardless of 1147 the expression level of its paired gene. 1148

1149 Table S1 . Clinical characteristics of 284 human samples, related to Figure Myeloid cells CLCA4  SULT2B1  TGM1  FOXQ1  KRT6A   DSG3   APOBEC3A   PPARA  SPRR1B   ANXA1  IFI6   IFI44   IFIT5   IFITM3  IFIT1  IFI16  ISG15  IFIT3  IFI35   SPRR2A TGFB1  TNFSF4  PF4V1  PF4  PPBP  TNF  CCL4  CCL4L2  IL1RN  CXCL8  CCL3L1  IL1B  CXCL2  CCL3  IL6  SCYL3  IL18  HBEGF  TNFSF10  TNFSF13  FTH1  TNFSF13B  CXCL16  CD40LG  LTB  TNFSF8  FGF23  IGF1  TXLNA  SCYL1  IL16  VEGFB  MIF  CCL5  IL32  CD70  IFNG  XCL2 

SCENIC: single-cell 1161 regulatory network inference and clustering

CoV-2 Drives Development of COVID-19

Host-Viral Infection Maps Reveal Signatures of Severe 1167 COVID-19 Patients

Near-optimal probabilistic 1169 RNA-seq quantification

Neuropilin-1 facilitates 1172 SARS-CoV-2 cell entry and infectivity

COVID-19: immunopathology and its implications for therapy

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-1177

Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

T cell responses in patients with COVID-19

An 1181 elaborate landscape of the human antibody repertoire against enterovirus 71 infection is 1182 revealed by phage display screening and deep sequencing

COVID-19 severity correlates with 1185 airway epithelium-immune cell interactions identified by single-cell analysis

Neuropilin-1 is a 1189 host factor for SARS-CoV-2 infection

Single-cell RNA-seq and V(D)J profiling of immune cells in COVID-19 patients. 1192 medRxiv

The dichotomous and incomplete adaptive immunity in COVID-19. medRxiv

Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-1198 FPR2/ALX anti-inflammatory system

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-1201 associated and tocilizumab-responding cytokine storm

SARS-CoV-2 Cell Entry 1204 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Reverse Genetics 1208 Reveals a Variable Infection Gradient in the Respiratory Tract

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Lineage Structure of the Human Antibody 1214 Repertoire in Response to Influenza Vaccination

Phenotypical and functional alteration of 1218 unconventional T cells in severe COVID-19 patients

Fast, sensitive and accurate 1221 integration of single-cell data with Harmony

S100A9 induces differentiation of acute myeloid leukemia cells through 1224 TLR4

Immunophenotyping of COVID-19 and influenza highlights the 1227 role of type I interferons in development of severe COVID-19

A major outbreak of severe acute respiratory syndrome in 1230

The Molecular Signatures Database (MSigDB) hallmark gene set collection

Platelet Gene Expression and 1236 Function in COVID-19 Patients

Deep immune profiling of 1239 COVID-19 patients reveals distinct immunotypes with therapeutic implications

The barcode, UMI, set format and 1241 BUStools

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-1244 19 Convalescent Individuals

Lung pathology of fatal severe acute respiratory syndrome

1249 FPR1 is the plague receptor on host immune cells

CoV-AbDab: the 1251 coronavirus antibody database

Reconstruction of 1253 cell spatial organization from single-cell RNA sequencing data based on ligand-receptor 1254 mediated self-assembly

Interferon-stimulated genes and their antiviral 1256 effector functions

Severe COVID-19 Is 1259 Marked by a Dysregulated Myeloid Cell Compartment

Elevated Calprotectin and Abnormal 1262

Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

A Single-Cell RNA Expression Map of 1264 Human Coronavirus Entry Factors

Comprehensive Integration of Single-Cell 1267 Data

Multi-Omics Resolves a Sharp Disease-State Shift 1270 between Mild and Moderate COVID-19

Annexin A1 and the 1272 Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and 1273 Clearance

SARS-CoV-2 entry factors 1276 are highly expressed in nasal epithelial cells together with innate immune genes

Transferrin receptor is another receptor for SARS-CoV-2 entry. bioRxiv

Pulmonary Megakaryocytes in Coronavirus Disease 1282 2019 (COVID-19): Roles in Thrombi and Fibrosis. Seminars in thrombosis and hemostasis 1283

XBP1 governs late events in plasma 1286 cell differentiation and is not required for antigen-specific memory B cell development. The

From Louvain to Leiden: guaranteeing 1289 well-connected communities

Mrp8 and Mrp14 are endogenous 1292 activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell 1296 sequencing

SCANPY: large-scale single-cell gene 1298 expression data analysis

Scrublet: Computational Identification of 1300

Single-cell Transcriptomic Landscape of Human Blood Cells

clusterProfiler: an R package for 1304 comparing biological themes among gene clusters

Activation of the 1306 megakaryocyte-specific gene platelet basic protein (PBP) by the Ets family factor PU.1

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild 1310 individuals

Single-cell landscape of immunological responses in patients 1313 with COVID-19

Lineage tracking reveals dynamic relationships of T cells in 1316 colorectal cancer

A human circulating immune cell landscape in aging and COVID-19

A pneumonia outbreak associated with a new coronavirus of 1322 probable bat origin